Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma

ObjectiveThe systemic immune-inflammation index (SII) based on neutrophil, platelet and lymphocyte counts, is a prognostic biomarker in some solid cancers. However, the prognostic value of SII has not yet been validated. This study was to evaluate the role of SII in predicting survival for patients with diffuse large B cell lymphoma (DLBCL).MethodsWe retrospectively investigated 224 patients with DLBCL between August 2005 and October 2018. Kaplan–Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.ResultsIn the ROC curve analysis, SII had the highest AUC and was more accurate as a prognostic factor. Patients with higher SII tended to have higher level of LDH, more advanced stage, poor PS, and high IPI score compared with low SII group. In univariate analyses, SII, PLR and NLR were all prognostic for progression-free survival and overall survival. Moreover, only SII, older age, HBSAg-positive and IPI were the independent prognostic factors for patients in multivariate analysis. The nomogram based on SII, older age, HBSAg status and IPI showed accurate prognostic ability for predicting 3-years and 5-years survival rates (c-index, 0.791) compared to the IPI alone (c-index, 0.716).ConclusionSII was a powerful tool for predicting outcome in patients with DLBCL. It might assist the separation of high-risk patients among patients with the same IPI.

Download Full-text

Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP

Blood ◽

10.1182/blood.v112.11.3782.3782 ◽

2008 ◽

Vol 112 (11) ◽

pp. 3782-3782

Author(s):

Jesse Shustik ◽

Christian Steidl ◽

Laurie Sehn ◽

Randy D Gascoyne

Keyword(s):

Overall Survival ◽

B Cell ◽

Prognostic Value ◽

Cell Lymphoma ◽

Prognostic Significance ◽

B Cell Lymphoma ◽

Immunohistochemical Analysis ◽

Prognostic Impact ◽

Large B Cell Lymphoma ◽

Large B Cell

Abstract Translocation of the BCL6 oncogene is the most commonly-detected chromosomal abnormality in diffuse large B-cell lymphoma (DLBCL), but its prognostic significance remains uncertain. BCL6 translocation has been associated with variable outcomes in prior clinical series, and its clinical impact has not been reevaluated since the introduction of rituximab (R). The objective of this study was to determine the prognostic value of BCL6 translocation in DLBCL patients treated with both CHOP and R-CHOP immunochemotherapy. Methods We included 163 DLBCL patients treated with CHOP (n=72) or R-CHOP (n=73) at the British Columbia Cancer Agency between the years 1999–2002. Formalin-fixed paraffin-embedded diagnostic lymph node specimens were analyzed for BCL6 translocation on tissue microarray (TMA) by fluorescence in situ hybridization (FISH), using commercially available dual-color break-apart probes (Abbott Molecular, IL, USA). Immunohistochemical analysis was performed for BCL6, CD10, and MUM1 expression, and cases were categorized as germinal centre B-cell-like (GCB) or non-GCB using a standard algorithm (Hans, Blood 2004). Results BCL6 translocation status was evaluable in 145 cases, and was positive (BCL6+) in 26% (37/145). Median age (65 vs. 59 years, p=0.03) and overall IPI score (p=0.03) were higher in the BCL6+ than in the BCL6− subgroup. Presence of BCL6 translocation correlated with non-GCB phenotype by immunohistochemical analysis (p=0.03), and showed no significant association with BCL6 protein expression (p=0.32). Median follow-up duration was 4.8 years (range, 0.1–8.4). BCL6 translocation was associated with a trend toward decreased overall survival (OS) among patients treated with R-CHOP (5-year OS 46.7% vs. 68%, p=0.098), though not among CHOP-treated patients (5-year OS 36.4% vs.49.5%, p=0.393). Kaplan-Meier analysis limited to the BCL6+ subgroup showed no overall survival difference between patients treated with CHOP and R-CHOP (p=0.67). Conclusions BCL6 translocations are found in approximately 25% of patients with de novo DLBCL. Presence of BCL6 translocation appears to predict unfavorable outcome in DLBCL patients treated with R-CHOP. However, the adverse prognostic impact of BCL6 translocation is confounded by an association with high IPI score and with non-GCB phenotype. Prospective analysis within large clinical trials would help to determine the independent prognostic value of this marker in the rituximab era.

Download Full-text

Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities

Annals of Hematology ◽

10.1007/s00277-017-3170-z ◽

2017 ◽

Vol 97 (2) ◽

pp. 267-276 ◽

Cited By ~ 9

Author(s):

Darko Antic ◽

Jelena Jelicic ◽

Goran Trajkovic ◽

Milena Todorovic Balint ◽

Jelena Bila ◽

...

Keyword(s):

B Cell ◽

Prognostic Value ◽

Cell Lymphoma ◽

Prognostic Significance ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Author response for "Prognostic significance of infectious episodes occurring during first-line therapy for diffuse large B-cell lymphoma - A nationwide cohort study"

10.1002/hon.2734/v2/response1 ◽

2020 ◽

Author(s):

Michael Roost Clausen ◽

Sinna Pilgaard Ulrichsen ◽

Maja Bech Juul ◽

Christian B. Poulsen ◽

Brian Østergaard ◽

...

Keyword(s):

Cohort Study ◽

B Cell ◽

Cell Lymphoma ◽

Prognostic Significance ◽

B Cell Lymphoma ◽

First Line ◽

First Line Therapy ◽

Large B Cell Lymphoma ◽

Line Therapy ◽

Large B Cell

Download Full-text

Prognostic significance of CD30 expression in diffuse large B cell lymphoma: A systematic review with meta‐analysis

Journal of Oral Pathology and Medicine ◽

10.1111/jop.13208 ◽

2021 ◽

Author(s):

Carla Isabelly Rodrigues‐Fernandes ◽

Lucas Guimarães Abreu ◽

Raghu Radhakrishnan ◽

Danyel Elias da Cruz Perez ◽

Gleyson Kleber Amaral‐Silva ◽

...

Keyword(s):

Systematic Review ◽

B Cell ◽

Cell Lymphoma ◽

Meta Analysis ◽

Prognostic Significance ◽

B Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH AT DIAGNOSIS (RDW) IN DIFFUSE LARGE B‐CELL LYMPHOMA

Hematological Oncology ◽

10.1002/hon.51_2881 ◽

2021 ◽

Vol 39 (S2) ◽

Author(s):

J.M. Raya ◽

P. López‐García ◽

C. D. Reyes ◽

M.J. Rodríguez‐Salazar ◽

C. De Bonis ◽

...

Keyword(s):

B Cell ◽

Prognostic Value ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Red Cell Distribution Width ◽

Red Cell ◽

Cell Distribution ◽

Distribution Width ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients

The Scientific World JOURNAL ◽

10.1100/2012/897178 ◽

2012 ◽

Vol 2012 ◽

pp. 1-7 ◽

Cited By ~ 6

Author(s):

Ying Huang ◽

Sheng Ye ◽

Yabing Cao ◽

Zhiming Li ◽

Jiajia Huang ◽

...

Keyword(s):

B Cell ◽

Germinal Center ◽

Survival Data ◽

Prognostic Value ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Chinese Patients ◽

First Line ◽

Large B Cell Lymphoma ◽

Large B Cell

Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%;P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%;P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%;P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL.

Download Full-text